# Amgen: Phase 1 study completed, 82 enrolled (Cardiometabolic Disease)

**Score:** 50/100

| Field | Value |
|---|---|
| Sponsor | Amgen |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | Single and Multiple Ascending Dose Study of AMG 513 in Participants With Obesity |
| NCT ID | NCT06585462 |
| Phase | Phase 1 |
| Status | completed |
| Conditions | Cardiometabolic Disease |
| Intervention types | drug |
| Target enrollment | 82 |
| Site countries | United States |
| Posted | 2024-09-05 |
| Planned start | 2024-09-09 |
| Event | Completed |
| Event date | 2026-09-16 |
| Last update posted | 2026-10-06 |

## Why this score
- Industry sponsor (buys outsourced services).
- Completed: closeout, analysis and the next study ahead.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT06585462). Last refreshed: 2026-11-05T08:46:16.625Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.